Surfactant Protein D Levels in Covid-19 Infection: Case-Control Study

Surfactant Protein D Levels in Covid-19 Infection: Case-Control Study

This study aims to provide some insight into the variation of SD-D protein levels in patients with Covid-19 (-) pneumonia, Covid-19 (+) pneumonia, and CT negative Covid-19 infection in comparison to the normal population through a larger number of cases. Objective of the study is to determine the serum surfactant protein D (SP-D) levels in Covid-19 pneumonia infection.

This study aims to provide some insight into the variation of SD-D protein levels in patients with Covid-19 (-) pneumonia, Covid-19 (+) pneumonia, and CT negative Covid-19 infection in comparison to the normal population through a larger number of cases. Subjects will assessed in accordance with the inclusion and exclusion criteria, they were divided into four groups as the CT (-), PCR (+) SARS-CoV-2 infection group, SARS-CoV-2 (+) Pneumonia Group, CT (+), PCR (-) Suspected Pneumonia Group and Healthy group (Control Group). Demographic data, medical history, vital findings (fever, blood pressure, sPO2), laboratory findings (complete blood count; C-reactive protein (CRP), D-dimer, Ferritin and hsTnT parameters) and radiological findings, time to onset of symptoms, Comorbid diseases, hospitalization location of the patients (service or ICU), clinical scores, CT severity scores will determine. SP-D level will analyze by the Enzyme-Linked Immunosorbent Assay (ELISA) method.

For patients;

Inclusion Criteria:

• who presented to the Covid-19 outpatient polyclinic of the ED with pneumonia symptoms,
• whose CT imaging's were compatible with Covid-19 pneumonia in accordance with the RSNAEC criteria and whose PCR tests were positive,
• whose SARS-CoV-2 PCR tests were positive as a result of contact tracing,
• who presented to the ED for further examination.
• who gave their written consent to participate in the study.
• Giving written consent to participate in the study.

Exclusion Criteria:

• diagnosis of kidney or liver failure
• acute pulmonary embolism
• chronic inflammatory disease history (rheumatological disease, autoimmune disease),
• pregnancy
• presence of any cancer diagnosis
• chronic obstructive pulmonary disease
• asthma disease,
• history of cerebrovascular disease.
• the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study.

For control group Inclusion Criteria

• no known acute, subacute or chronic disease history
• not suffer from any infection in the last fortnight,
• not to be on a particular medication,
• Presenting to the ED with reasons other than infectious complaints
• Giving written consent to participate in the study.

Exclusion Criteria:

• diagnosis of kidney or liver failure
• acute pulmonary embolism
• chronic inflammatory disease history (rheumatological disease, autoimmune disease),
• pregnancy
• presence of any cancer diagnosis
• chronic obstructive pulmonary disease
• asthma disease,
• history of cerebrovascular disease.